25 XP   0   0   10

SciClone Pharmaceuticals
Buy, Hold or Sell?

Let's analyse Sciclone together

PenkeI guess you are interested in SciClone Pharmaceuticals. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of SciClone Pharmaceuticals. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about SciClone Pharmaceuticals

I send you an email if I find something interesting about SciClone Pharmaceuticals.

Quick analysis of Sciclone (30 sec.)










What can you expect buying and holding a share of Sciclone? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.17
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
HK$4.80
Expected worth in 1 year
HK$9.27
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
HK$5.79
Return On Investment
32.1%

For what price can you sell your share?

Current Price per Share
HK$18.04
Expected price per share
HK$16.04 - HK$18.14
How sure are you?
50%

1. Valuation of Sciclone (5 min.)




Live pricePrice per Share (EOD)

HK$18.04

Intrinsic Value Per Share

HK$8.03 - HK$22.75

Total Value Per Share

HK$12.83 - HK$27.55

2. Growth of Sciclone (5 min.)




Is Sciclone growing?

Current yearPrevious yearGrowGrow %
How rich?$413.2m$320m$93.1m22.6%

How much money is Sciclone making?

Current yearPrevious yearGrowGrow %
Making money$118.1m$127.5m-$9.3m-8.0%
Net Profit Margin31.1%36.7%--

How much money comes from the company's main activities?

3. Financial Health of Sciclone (5 min.)




What can you expect buying and holding a share of Sciclone? (5 min.)

Welcome investor! Sciclone's management wants to use your money to grow the business. In return you get a share of Sciclone.

What can you expect buying and holding a share of Sciclone?

First you should know what it really means to hold a share of Sciclone. And how you can make/lose money.

Speculation

The Price per Share of Sciclone is HK$18.04. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sciclone.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sciclone, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$4.80. Based on the TTM, the Book Value Change Per Share is HK$1.12 per quarter. Based on the YOY, the Book Value Change Per Share is HK$3.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.33 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sciclone.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps0.181.0%0.181.0%0.191.0%0.150.8%0.130.7%
Usd Book Value Change Per Share0.140.8%0.140.8%0.412.3%0.080.5%0.100.6%
Usd Dividend Per Share0.040.2%0.040.2%0.170.9%0.160.9%0.150.9%
Usd Total Gains Per Share0.181.0%0.181.0%0.573.2%0.251.4%0.261.4%
Usd Price Per Share1.06-1.06-1.10-0.43-0.36-
Price to Earnings Ratio6.05-6.05-5.90-2.39-1.99-
Price-to-Total Gains Ratio5.73-5.73-1.92-3.83-3.83-
Price to Book Ratio1.73-1.73-2.35-0.82-0.68-
Price-to-Total Gains Ratio5.73-5.73-1.92-3.83-3.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.303708
Number of shares434
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.16
Usd Book Value Change Per Share0.140.08
Usd Total Gains Per Share0.180.25
Gains per Quarter (434 shares)80.19106.54
Gains per Year (434 shares)320.77426.15
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
173248311281145416
2146495632563289842
32197439538444341268
4292991127411265791694
53651239159514077242120
64381486191616898682546
751117342237197010132972
858419822558225111583398
965822292879253313033824
1073124773200281414474250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%

Fundamentals of Sciclone

About SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-18 17:07:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of SciClone Pharmaceuticals.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sciclone earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 31.1% means that $0.31 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SciClone Pharmaceuticals:

  • The MRQ is 31.1%. The company is making a huge profit. +2
  • The TTM is 31.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ31.1%TTM31.1%0.0%
TTM31.1%YOY36.7%-5.6%
TTM31.1%5Y36.2%-5.1%
5Y36.2%10Y30.4%+5.8%
1.1.2. Return on Assets

Shows how efficient Sciclone is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • 19.8% Return on Assets means that Sciclone generated $0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SciClone Pharmaceuticals:

  • The MRQ is 19.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 19.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ19.8%TTM19.8%0.0%
TTM19.8%YOY22.7%-2.9%
TTM19.8%5Y28.6%-8.9%
5Y28.6%10Y24.1%+4.5%
1.1.3. Return on Equity

Shows how efficient Sciclone is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • 28.6% Return on Equity means Sciclone generated $0.29 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SciClone Pharmaceuticals:

  • The MRQ is 28.6%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 28.6%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ28.6%TTM28.6%0.0%
TTM28.6%YOY39.8%-11.3%
TTM28.6%5Y80.3%-51.8%
5Y80.3%10Y67.3%+13.1%

1.2. Operating Efficiency of SciClone Pharmaceuticals.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sciclone is operating .

  • Measures how much profit Sciclone makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SciClone Pharmaceuticals:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY43.6%-43.6%
TTM-5Y32.0%-32.0%
5Y32.0%10Y29.8%+2.2%
1.2.2. Operating Ratio

Measures how efficient Sciclone is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.84 means that the operating costs are $0.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of SciClone Pharmaceuticals:

  • The MRQ is 0.845. The company is less efficient in keeping operating costs low.
  • The TTM is 0.845. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.845TTM0.8450.000
TTM0.845YOY0.812+0.032
TTM0.8455Y0.829+0.016
5Y0.82910Y0.851-0.022

1.3. Liquidity of SciClone Pharmaceuticals.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sciclone is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.04 means the company has $4.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of SciClone Pharmaceuticals:

  • The MRQ is 4.039. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.039. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.039TTM4.0390.000
TTM4.039YOY3.135+0.904
TTM4.0395Y3.652+0.387
5Y3.65210Y3.472+0.180
1.3.2. Quick Ratio

Measures if Sciclone is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 3.21 means the company can pay off $3.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SciClone Pharmaceuticals:

  • The MRQ is 3.206. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.206. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.206TTM3.2060.000
TTM3.206YOY2.921+0.286
TTM3.2065Y3.250-0.043
5Y3.25010Y3.122+0.127

1.4. Solvency of SciClone Pharmaceuticals.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sciclone assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sciclone to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.31 means that Sciclone assets are financed with 30.7% credit (debt) and the remaining percentage (100% - 30.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of SciClone Pharmaceuticals:

  • The MRQ is 0.307. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.307. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.307TTM0.3070.000
TTM0.307YOY0.430-0.122
TTM0.3075Y0.400-0.092
5Y0.40010Y0.388+0.012
1.4.2. Debt to Equity Ratio

Measures if Sciclone is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 44.4% means that company has $0.44 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SciClone Pharmaceuticals:

  • The MRQ is 0.444. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.444. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.444TTM0.4440.000
TTM0.444YOY0.753-0.309
TTM0.4445Y1.979-1.535
5Y1.97910Y1.730+0.249

2. Market Valuation of SciClone Pharmaceuticals

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sciclone generates.

  • Above 15 is considered overpriced but always compare Sciclone to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 6.05 means the investor is paying $6.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SciClone Pharmaceuticals:

  • The EOD is 13.159. Based on the earnings, the company is underpriced. +1
  • The MRQ is 6.047. Based on the earnings, the company is cheap. +2
  • The TTM is 6.047. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD13.159MRQ6.047+7.112
MRQ6.047TTM6.0470.000
TTM6.047YOY5.902+0.145
TTM6.0475Y2.390+3.657
5Y2.39010Y1.992+0.398
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of SciClone Pharmaceuticals:

  • The EOD is 11.399. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.238. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 5.238. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD11.399MRQ5.238+6.161
MRQ5.238TTM5.2380.000
TTM5.238YOY6.498-1.260
TTM5.2385Y2.347+2.891
5Y2.34710Y1.956+0.391
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sciclone is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of SciClone Pharmaceuticals:

  • The EOD is 3.762. Based on the equity, the company is fair priced.
  • The MRQ is 1.729. Based on the equity, the company is underpriced. +1
  • The TTM is 1.729. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.762MRQ1.729+2.033
MRQ1.729TTM1.7290.000
TTM1.729YOY2.352-0.623
TTM1.7295Y0.816+0.913
5Y0.81610Y0.680+0.136
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of SciClone Pharmaceuticals compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.1171.1170%3.181-65%0.653+71%0.799+40%
Book Value Per Share--4.7964.7960%3.678+30%2.614+83%2.433+97%
Current Ratio--4.0394.0390%3.135+29%3.652+11%3.472+16%
Debt To Asset Ratio--0.3070.3070%0.430-28%0.400-23%0.388-21%
Debt To Equity Ratio--0.4440.4440%0.753-41%1.979-78%1.730-74%
Dividend Per Share--0.3300.3300%1.313-75%1.269-74%1.208-73%
Eps--1.3711.3710%1.466-6%1.175+17%0.984+39%
Free Cash Flow Per Share--1.5831.5830%1.331+19%1.110+43%0.963+64%
Free Cash Flow To Equity Per Share--0.5080.5080%1.515-66%0.667-24%0.467+9%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--22.751--------
Intrinsic Value_10Y_min--8.034--------
Intrinsic Value_1Y_max--1.470--------
Intrinsic Value_1Y_min--1.044--------
Intrinsic Value_3Y_max--5.034--------
Intrinsic Value_3Y_min--2.948--------
Intrinsic Value_5Y_max--9.342--------
Intrinsic Value_5Y_min--4.631--------
Market Cap11104865192.960+50%5593949412.0005593949412.0000%5893887374.950-5%2297567357.390+143%1914639464.492+192%
Net Profit Margin--0.3110.3110%0.367-15%0.362-14%0.304+2%
Operating Margin----0%0.436-100%0.320-100%0.298-100%
Operating Ratio--0.8450.8450%0.812+4%0.829+2%0.851-1%
Pb Ratio3.762+54%1.7291.7290%2.352-26%0.816+112%0.680+154%
Pe Ratio13.159+54%6.0476.0470%5.902+2%2.390+153%1.992+204%
Price Per Share18.040+54%8.2908.2900%8.650-4%3.388+145%2.823+194%
Price To Free Cash Flow Ratio11.399+54%5.2385.2380%6.498-19%2.347+123%1.956+168%
Price To Total Gains Ratio12.468+54%5.7295.7290%1.925+198%3.827+50%3.827+50%
Quick Ratio--3.2063.2060%2.921+10%3.250-1%3.122+3%
Return On Assets--0.1980.1980%0.227-13%0.286-31%0.241-18%
Return On Equity--0.2860.2860%0.398-28%0.803-64%0.673-58%
Total Gains Per Share--1.4471.4470%4.494-68%1.922-25%2.007-28%
Usd Book Value--413240163.023413240163.0230%320051541.230+29%226205803.715+83%210599696.601+96%
Usd Book Value Change Per Share--0.1430.1430%0.406-65%0.083+71%0.102+40%
Usd Book Value Per Share--0.6120.6120%0.470+30%0.334+83%0.311+97%
Usd Dividend Per Share--0.0420.0420%0.168-75%0.162-74%0.154-73%
Usd Eps--0.1750.1750%0.187-6%0.150+17%0.126+39%
Usd Free Cash Flow--136372228.634136372228.6340%115823068.162+18%96104458.874+42%83380891.112+64%
Usd Free Cash Flow Per Share--0.2020.2020%0.170+19%0.142+43%0.123+64%
Usd Free Cash Flow To Equity Per Share--0.0650.0650%0.193-66%0.085-24%0.060+9%
Usd Market Cap1418091285.141+50%714347339.912714347339.9120%752649417.781-5%293399351.539+143%244499459.616+192%
Usd Price Per Share2.304+54%1.0591.0590%1.105-4%0.433+145%0.361+194%
Usd Profit--118130983.430118130983.4300%127523125.476-7%101705079.106+16%85204969.596+39%
Usd Revenue--379751706.192379751706.1920%347820273.879+9%284602481.998+33%265088695.414+43%
Usd Total Gains Per Share--0.1850.1850%0.574-68%0.245-25%0.256-28%
 EOD+4 -4MRQTTM+0 -0YOY+15 -205Y+19 -1610Y+24 -11

3.2. Fundamental Score

Let's check the fundamental score of SciClone Pharmaceuticals based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.159
Price to Book Ratio (EOD)Between0-13.762
Net Profit Margin (MRQ)Greater than00.311
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.206
Current Ratio (MRQ)Greater than14.039
Debt to Asset Ratio (MRQ)Less than10.307
Debt to Equity Ratio (MRQ)Less than10.444
Return on Equity (MRQ)Greater than0.150.286
Return on Assets (MRQ)Greater than0.050.198
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of SciClone Pharmaceuticals based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5082.206
Ma 20Greater thanMa 5017.188
Ma 50Greater thanMa 10014.614
Ma 100Greater thanMa 20013.734
OpenGreater thanClose18.000
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,320,406
Total Liabilities1,328,244
Total Stockholder Equity2,992,162
 As reported
Total Liabilities 1,328,244
Total Stockholder Equity+ 2,992,162
Total Assets = 4,320,406

Assets

Total Assets4,320,406
Total Current Assets3,600,487
Long-term Assets719,919
Total Current Assets
Cash And Cash Equivalents 1,671,829
Short-term Investments 202,701
Net Receivables 780,962
Inventory 140,560
Other Current Assets 804,435
Total Current Assets  (as reported)3,600,487
Total Current Assets  (calculated)3,600,487
+/-0
Long-term Assets
Property Plant Equipment 28,625
Intangible Assets 542,241
Other Assets 5,952
Long-term Assets  (as reported)719,919
Long-term Assets  (calculated)576,818
+/- 143,101

Liabilities & Shareholders' Equity

Total Current Liabilities891,432
Long-term Liabilities436,812
Total Stockholder Equity2,992,162
Total Current Liabilities
Short Long Term Debt 417,876
Accounts payable 102,717
Total Current Liabilities  (as reported)891,432
Total Current Liabilities  (calculated)520,593
+/- 370,839
Long-term Liabilities
Long term Debt Total 422,037
Other Liabilities 14,775
Long-term Liabilities  (as reported)436,812
Long-term Liabilities  (calculated)436,812
+/-0
Total Stockholder Equity
Common Stock237
Retained Earnings 934,019
Capital Surplus 1,710,429
Other Stockholders Equity 196,075
Total Stockholder Equity (as reported)2,992,162
Total Stockholder Equity (calculated)2,840,760
+/- 151,402
Other
Capital Stock237
Cash And Equivalents1,671,829
Cash and Short Term Investments 1,874,530
Common Stock Shares Outstanding 674,783
Liabilities and Stockholders Equity 4,320,406
Net Invested Capital 3,824,720
Net Tangible Assets 2,449,921
Net Working Capital 2,709,055
Property Plant and Equipment Gross 94,987



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
0
1,427,651
1,296,277
1,845,823
2,882,644
4,062,682
4,320,406
4,320,4064,062,6822,882,6441,845,8231,296,2771,427,6510
   > Total Current Assets 
195,733
1,143,008
1,055,829
1,572,016
1,908,914
2,999,060
3,600,487
3,600,4872,999,0601,908,9141,572,0161,055,8291,143,008195,733
       Cash And Cash Equivalents 
0
481,629
275,962
919,490
1,118,986
2,127,488
1,671,829
1,671,8292,127,4881,118,986919,490275,962481,6290
       Short-term Investments 
0
129,488
8,698
123,761
70,013
60,188
202,701
202,70160,18870,013123,7618,698129,4880
       Net Receivables 
41,510
364,084
613,430
379,227
324,791
546,512
780,962
780,962546,512324,791379,227613,430364,08441,510
       Inventory 
16,587
152,224
145,401
140,199
171,585
174,660
140,560
140,560174,660171,585140,199145,401152,22416,587
   > Long-term Assets 
0
284,643
240,448
273,807
973,730
1,063,622
719,919
719,9191,063,622973,730273,807240,448284,6430
       Property Plant Equipment 
2,002
47,777
52,437
35,103
14,264
29,878
28,625
28,62529,87814,26435,10352,43747,7772,002
       Intangible Assets 
0
127,067
143,468
169,251
652,691
606,095
542,241
542,241606,095652,691169,251143,468127,0670
       Long-term Assets Other 
0
0
0
0
5,151
5,156
5,301
5,3015,1565,1510000
> Total Liabilities 
0
467,753
253,406
320,646
2,570,782
1,745,274
1,328,244
1,328,2441,745,2742,570,782320,646253,406467,7530
   > Total Current Liabilities 
26,441
444,557
230,314
306,599
1,387,771
956,770
891,432
891,432956,7701,387,771306,599230,314444,55726,441
       Short Long Term Debt 
0
0
0
0
782,988
382,542
417,876
417,876382,542782,9880000
       Accounts payable 
3,645
38,252
52,576
66,047
57,546
126,920
102,717
102,717126,92057,54666,04752,57638,2523,645
       Other Current Liabilities 
5,335
258,936
43,735
75,937
350,194
177,016
0
0177,016350,19475,93743,735258,9365,335
   > Long-term Liabilities 
0
23,196
23,092
14,047
1,183,011
788,504
436,812
436,812788,5041,183,01114,04723,09223,1960
       Long term Debt Total 
0
19,642
17,354
6,992
1,173,559
773,335
422,037
422,037773,3351,173,5596,99217,35419,6420
       Capital Lease Obligations Min Short Term Debt
0
38,782
39,560
26,458
8,472
22,566
20,069
20,06922,5668,47226,45839,56038,7820
       Long-term Liabilities Other 
0
579
800
815
194
188
205
2051881948158005790
> Total Stockholder Equity
0
959,898
1,042,871
1,525,177
311,862
2,317,408
2,992,162
2,992,1622,317,408311,8621,525,1771,042,871959,8980
   Common Stock
51
0
0
0
192
232
237
23723219200051
   Retained Earnings Total Equity0000000
   Accumulated Other Comprehensive Income 0000000
   Capital Surplus 
0
0
0
0
0
1,727,026
1,710,429
1,710,4291,727,02600000
   Treasury Stock0000000
   Other Stockholders Equity 
-1,520
1,660,957
1,208,848
1,288,146
147,098
273,918
196,075
196,075273,918147,0981,288,1461,208,8481,660,957-1,520



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue2,749,681
Cost of Revenue-679,196
Gross Profit2,070,4852,070,485
 
Operating Income (+$)
Gross Profit2,070,485
Operating Expense-1,643,685
Operating Income950,604426,800
 
Operating Expense (+$)
Research Development123,860
Selling General Administrative847,887
Selling And Marketing Expenses-
Operating Expense1,643,685971,747
 
Net Interest Income (+$)
Interest Income10,524
Interest Expense-155,778
Other Finance Cost-134,730
Net Interest Income-10,524
 
Pretax Income (+$)
Operating Income950,604
Net Interest Income-10,524
Other Non-Operating Income Expenses-
Income Before Tax (EBT)940,080950,604
EBIT - interestExpense = -155,778
940,080
1,011,133
Interest Expense155,778
Earnings Before Interest and Taxes (EBIT)-1,095,858
Earnings Before Interest and Taxes (EBITDA)1,105,570
 
After tax Income (+$)
Income Before Tax940,080
Tax Provision-84,725
Net Income From Continuing Ops855,355855,355
Net Income855,355
Net Income Applicable To Common Shares855,355
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-10,524
 

Technical Analysis of Sciclone
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sciclone. The general trend of Sciclone is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sciclone's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of SciClone Pharmaceuticals.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 18.14.

The bearish price targets are: 16.10 > 16.04 > 16.04.

Tweet this
SciClone Pharmaceuticals Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of SciClone Pharmaceuticals. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

SciClone Pharmaceuticals Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of SciClone Pharmaceuticals. The current macd is 1.01265521.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sciclone price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sciclone. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sciclone price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
SciClone Pharmaceuticals Daily Moving Average Convergence/Divergence (MACD) ChartSciClone Pharmaceuticals Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of SciClone Pharmaceuticals. The current adx is 64.62.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sciclone shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
SciClone Pharmaceuticals Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of SciClone Pharmaceuticals. The current sar is 16.82.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
SciClone Pharmaceuticals Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of SciClone Pharmaceuticals. The current rsi is 82.21. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
SciClone Pharmaceuticals Daily Relative Strength Index (RSI) ChartSciClone Pharmaceuticals Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of SciClone Pharmaceuticals. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sciclone price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
SciClone Pharmaceuticals Daily Stochastic Oscillator ChartSciClone Pharmaceuticals Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of SciClone Pharmaceuticals. The current cci is 62.48.

SciClone Pharmaceuticals Daily Commodity Channel Index (CCI) ChartSciClone Pharmaceuticals Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of SciClone Pharmaceuticals. The current cmo is 71.68.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
SciClone Pharmaceuticals Daily Chande Momentum Oscillator (CMO) ChartSciClone Pharmaceuticals Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of SciClone Pharmaceuticals. The current willr is -10.71428571.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
SciClone Pharmaceuticals Daily Williams %R ChartSciClone Pharmaceuticals Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of SciClone Pharmaceuticals.

SciClone Pharmaceuticals Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of SciClone Pharmaceuticals. The current atr is 0.32653463.

SciClone Pharmaceuticals Daily Average True Range (ATR) ChartSciClone Pharmaceuticals Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of SciClone Pharmaceuticals. The current obv is 56,005,117.

SciClone Pharmaceuticals Daily On-Balance Volume (OBV) ChartSciClone Pharmaceuticals Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of SciClone Pharmaceuticals. The current mfi is 81.36.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
SciClone Pharmaceuticals Daily Money Flow Index (MFI) ChartSciClone Pharmaceuticals Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for SciClone Pharmaceuticals.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

SciClone Pharmaceuticals Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of SciClone Pharmaceuticals based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5082.206
Ma 20Greater thanMa 5017.188
Ma 50Greater thanMa 10014.614
Ma 100Greater thanMa 20013.734
OpenGreater thanClose18.000
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sciclone with someone you think should read this too:
  • Are you bullish or bearish on Sciclone? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sciclone? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about SciClone Pharmaceuticals

I send you an email if I find something interesting about SciClone Pharmaceuticals.


Comments

How you think about this?

Leave a comment

Stay informed about SciClone Pharmaceuticals.

Receive notifications about SciClone Pharmaceuticals in your mailbox!